Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metabolic syndrome and endothelial dysfunction.

Alessia Fornoni1, Leopoldo Raij

  • 1Division of Nephrology and Hypertension, University of Miami School of Medicine and Veterans Affairs Medical Center, 1201 NW 16th Street, Room A-1009, Miami, FL 33125, USA.

Current Hypertension Reports
|March 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nephrology in the Paradigm of Cardiovascular-Kidney-Metabolic Health: Report of an ASN Initiative on Saving Kidneys, Hearts, and Lives.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Between challenges and commitments, freedom and rules, the lesson of Claudio Ponticelli.

Journal of nephrology·2026
Same author

CRITICAL ROLE OF DYSREGULATED AUTOPHAGY IN PATHOPHYSIOLOGY OF PODOCYTOPATHY.

Kidney360·2026
Same author

Memories of Claudio Ponticelli.

Kidney international·2026
Same author

More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases.

Drugs·2026
Same author

Targeting SMPDL3B to Ameliorate Radiation- and Cisplatin-Induced Renal Toxicity.

Cells·2026
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

Metabolic syndrome, marked by increasing incidence, involves endothelial dysfunction, a key factor in cardiovascular disease. Understanding this dysfunction may lead to new preventive and therapeutic strategies.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disorders
  • Vascular Biology

Background:

  • Metabolic syndrome incidence is rising, posing significant cardiovascular risks.
  • Endothelial dysfunction is an early event in metabolic syndrome, predicting vascular events.
  • It signifies uncontrolled atherosclerotic risk, exacerbating genetic predispositions.

Purpose of the Study:

  • To explore the role of endothelial dysfunction in metabolic syndrome.
  • To identify potential therapeutic targets for cardiovascular disease prevention.

Main Methods:

  • Review of clinical and experimental data on metabolic syndrome and endothelial dysfunction.
  • Analysis of agents affecting endothelial function, such as renin-angiotensin-aldosterone system inhibitors and statins.

Related Experiment Videos

Main Results:

  • Endothelial dysfunction is a predictor of vascular events in metabolic syndrome.
  • Agents like RAAS inhibitors and statins can restore endothelial function.
  • Improvement in endothelial function is not yet a validated surrogate endpoint for cardiovascular outcomes.

Conclusions:

  • Understanding the mechanisms of endothelial dysfunction in metabolic syndrome is crucial.
  • This knowledge can guide the development of preventive and early therapeutic interventions.
  • Targeting endothelial dysfunction may mitigate cardiovascular morbidity and mortality associated with metabolic syndrome.